FAQ on Calidi Biotherapeutics Inc.'s Appointment of Dr. Guy Travis Clifton as Chief Medical Officer

Who has Calidi Biotherapeutics Inc. appointed as its new Chief Medical Officer?

Calidi Biotherapeutics Inc. has appointed Dr. Guy Travis Clifton as its new Chief Medical Officer, Consultant, and Advisor.

What expertise does Dr. Guy Travis Clifton bring to Calidi Biotherapeutics?

Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership roles at Parthenon Therapeutics and experience as a surgical oncologist in the U.S. Army.

What is CLD-201?

CLD-201 is a virotherapy for solid tumors, currently under clinical development by Calidi Biotherapeutics, following a recently filed Investigational New Drug application.

How does Dr. Clifton’s appointment benefit Calidi Biotherapeutics?

Dr. Clifton’s extensive experience in immunotherapy is expected to bolster Calidi’s efforts in developing stem cell-based and enveloped virus cancer therapies.

What is Calidi Biotherapeutics’ specialization?

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer, using novel stem cell-based platforms and enveloped virotherapies.

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in San Diego, California.

Where can I find more information about Calidi Biotherapeutics?

For more information, please visit www.calidibio.com.

What is the significance of Calidi Biotherapeutics’ technology?

Calidi’s technology is designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety in treating cancer.

What types of cancer is Calidi Biotherapeutics targeting with its therapies?

Calidi Biotherapeutics is targeting multiple oncology indications, including high-grade gliomas and solid tumors, with its therapies.

Where can I view the full press release about Dr. Clifton’s appointment?

To view the full press release, visit: https://ibn.fm/qXoi9.